These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 27192120)

  • 1. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
    Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
    Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
    Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
    Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
    Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.
    Serrano D; Bleau AM; Fernandez-Garcia I; Fernandez-Marcelo T; Iniesta P; Ortiz-de-Solorzano C; Calvo A
    Mol Cancer; 2011 Aug; 10():96. PubMed ID: 21827695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
    Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
    Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
    Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
    Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Telomere Biology in Acute Lymphoblastic Leukemia.
    Karow A; Haubitz M; Oppliger Leibundgut E; Helsen I; Preising N; Steiner D; Dantonello TM; Ammann RA; Roessler J; Kartal-Kaess M; Röth A; Baerlocher GM
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
    Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
    Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.
    Jackson SR; Zhu CH; Paulson V; Watkins L; Dikmen ZG; Gryaznov SM; Wright WE; Shay JW
    Cancer Res; 2007 Feb; 67(3):1121-9. PubMed ID: 17283146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.